(Cision Via Acquire Media NewsEdge) Lars Christian Stugaard (32) has been appointed as acting Chief Executive Officer (CEO) of DiaGenic ASA on an interim basis effective from 1st April 2014. Mr. Stugaard holds the position as CEO in Strata Marine & Offshore AS and has worked in the Ferncliff group since 2003. During his 11 year tenure with Ferncliff, he has been working with financial management, general business development and analysis. He holds a BSc from the Norwegian School of Management in Oslo.
Hanne Skaarberg Holen, Chairman of the Board, +47 982 94 591 About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com
This information was brought to you by Cision http://news.cision.comhttp://news.cision.com/diagenic-asa/r/new-ceo,c9554976
(c) 2014 Cision. All Rights Reserved.
[ Back To TMCnet.com's Homepage ]